MeiraGTx报告AAV-GAD在帕金森氏病中取得了积极的成果,运动功能有18点改善,没有发生严重不良事件。 MeiraGTx reports positive phase 2 results for AAV-GAD in Parkinson's disease, with 18-point motor function improvement and no serious adverse events.

MeiraGTx控股公司报告说,它对AAV-GAD治疗帕金森病的临床研究取得了积极成果,有14人参加。 MeiraGTx Holdings has reported positive results from its clinical study of AAV-GAD for Parkinson's disease, involving 14 participants. 治疗是安全的,没有发生严重不良事件,高剂量群体在26周后运动功能有18点改善。 The treatment was safe, with no serious adverse events, and the high-dose group showed an 18-point improvement in motor function after 26 weeks. 两个剂量组也都报告生活质量有所提高。 Both dosage groups also reported better quality of life. 之后MGTX股票上涨了13.2%。 Following the news, MGTX stock rose by 13.2%. 该公司目前正在计划第3阶段的试验。 The company is now planning a phase 3 trial.